The HSE states that asthma is the most common chronic respiratory disease in the Republic of Ireland affecting people of all ages and all socio-economic groups. Ireland has the fourth highest prevalence of asthma worldwide, and current estimates suggest that approximately 1 in 10 of our population are affected. Asthma is often under-diagnosed and uncontrolled, creating a substantial burden of ill-health to individuals, their families and the economy.
The aim of this course is to review the pathophysiology of asthma, current management guidelines and enhance medicines optimisation in patients with asthma.
Depression is a very common condition which affects 1 in 10 people at any one time; 450,000 people in Ireland may be affected. Community pharmacists are often the first healthcare professional that patients may discuss concerns or symptoms of depression with.
The aim of this course is to provide an overview of current guidelines on the management of depression, to enhance patient outcomes of this condition.
The outcomes for patients who develop Acute Coronary Syndromes (ACS) has improved dramatically over the past 25 years, due to the use of Dual Anti Platelet therapy (DAPT) in ACS and more intensive secondary prevention.
The aim of this course is to provide an overview of DAPT in ACS, and secondary prevention guidelines and drug treatment options.
With the growing number of drugs coming to market and the increasing complexity of drug therapies, the incidence and severity of drug interactions is on the rise. This course will provide an overview of the epidemiology, mechanisms and risk factors for drug interactions.
The aim of this course is to provide an update on how to manage, minimise and report drug interactions.
Type 2 diabetes (T2DM) accounts for 90 – 95% of all diabetes, with an asymptomatic phase which may last years. Approximately 15 – 20% of people with T2DM in Ireland may be undiagnosed and it is recognised that the longer a person lives with undiagnosed diabetes, the worse the health outcomes.
The aim of the course is to review the pathophysiology of T2DM and current treatment options for T2DM and the known complications of T2DM.